Why Is TEVA PHARMACEUTICAL (TEVA) Stock Moving Today?

Why TEVA stock is up today

TEVA stock rose 9.60% to $34.71 in the latest session as the company delivered better-than-expected revenue and raised its full-year outlook for key innovative brands. The move followed the release of Q2 2026 earnings results that highlighted strong performance from AUSTEDO, AJOVY, and UZEDY, which offset a decline in generic revenue and an earnings miss driven by acquisition-related expenses. The company also announced plans to transition to a direct listing on the NYSE, effective September 14, 2026, which added to investor optimism.

What Happened

Teva reported second-quarter revenue of $4.142 billion, exceeding the $4.047 billion estimate. While adjusted earnings per share of $0.02 fell short of the $0.25 forecast, the company raised its 2026 revenue guidance for its innovative brands. AUSTEDO, AJOVY, and UZEDY are now expected to generate $2.45 billion to $2.6 billion, $850 million to $870 million, and $77 million in net sales, respectively. UZEDY alone saw record Q2 net sales of $77 million, a 43% year-over-year increase. Teva also raised its full-year revenue guidance to a range of $16.5 billion to $16.85 billion. Despite lowering its adjusted EPS guidance to $1.91 to $2.11, the company emphasized long-term growth through its innovative portfolio and structural changes.

What The Data Shows

TEVA’s stock has traded between $14.99 and $37.34 over the past 52 weeks. The stock’s beta of 0.86 suggests it is less volatile than the broader market. Intraday volume was unusually high, with unusual options activity including three notable prints. Call premiums totaled $495,000, while put premiums reached $630,000, with the largest single print at $630,000. Recent insider transactions show six sales over the past 90 days, totaling $11.6 million, with no buys reported.

What To Watch

Teva has not scheduled earnings for the near term, but investors will closely monitor the company’s progress toward its revised revenue guidance and the impact of its direct listing on the NYSE beginning September 14, 2026. Coverage breadth is also a key factor as the market digests the updated outlook for its innovative brands.

Why is TEVA stock moving today?

TEVA PHARMACEUTICAL (TEVA) is drawing unusual attention today. Our newswire has captured 31 stories on TEVA across 11 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100). The most recent driver: "Q3 2026 Teva Pharmaceutical Industries Limited Earnings Call Transcript" (GuruFocus).

Is TEVA a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of TEVA coverage reads 55/100 over 31 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.